secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263543
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.
- First patient dosing in REVEAL pivotal trial scheduled Q4 2025; enrollment to continue at multiple sites.
- Regained full unencumbered rights to TSHA-102 after Astellas option agreement expired in October 2025.
- Q3 2025 net loss $32.7M ($0.09/share); R&D $25.7M; cash $297.3M expected to fund operations into 2028.
- David McNinch appointed Chief Commercial Officer in September 2025; TSHA-102 generally well tolerated with no treatment-related SAEs in 12 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/0001193125-25-263543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/d17004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer